Matching-adjusted indirect comparison
11 evidence topics · 2 sources
Objective
Comparative objective
Location and study date
Not applicable.
Study design
Indirect comparative design
Eligibility criteria
Comparator population
Treatment
Treatment exposure
| Characteristic | Quoted value |
|---|---|
| Cytisinicline course | “12 weeks” |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Abstinence assessment intervals
| Characteristic | Quoted value |
|---|---|
| End of treatment | “Weeks 9-12” |
| Longer follow-up | “Weeks 9-24” |
Statistical analysis description
Number of participants (Planned and analyzed)
Contributing cytisinicline trials
| Characteristic | Quoted value |
|---|---|
| Trials pooled | “ORCA-2 and ORCA-3” |
Description of analysis sets
Adjustment approach
Results
Participant disposition
Not applicable.
Baseline characteristics
No evidence found.
Efficacy results
Adjusted continuous-abstinence estimates
| Assessment | Quoted estimate |
|---|---|
| Continuous abstinence, weeks 9–12 | “adjusted OR, 1.33; 95% CI, 0.86-2.05” |
| Continuous abstinence, weeks 9–24 | “adjusted OR, 1.95; 95% CI, 1.13-3.34” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adjusted nausea estimate
| Assessment | Quoted estimate |
|---|---|
| Nausea | “adjusted OR, 0.18; 95% CI, 0.10-0.31” |
Study limitations
Summary
This is an indirect comparison, not a randomized head-to-head trial. Weighting cannot remove confounding from unmeasured differences between trials. The weeks 9–12 odds-ratio confidence interval includes no difference, while the weeks 9–24 interval does not. These estimates should not be interpreted as head-to-head evidence.